Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., trading under the ticker DECA, filed an 8-K current report with the SEC on September 4, 2025, accession number 0001213900-25-084180. Semnur is a clinical-stage biopharmaceutical company that emerged from a SPAC business combination with Decathlon Acquisition Corp., a healthcare-focused blank-check vehicle that completed its IPO in 2021. The company is developing treatments targeting spinal and pain-related conditions, positioning it within the specialty pharmaceutical and pain management sector. The September 2025 filing reflects continued post-merger reporting obligations under the combined public entity. For complete filing history, sponsor details, and deal analytics on DECA, sign up for full access at SpacDesk.